Key result
Runcaciguat significantly reduced proteinuria, decreased kidney injury biomarkers, and attenuated morphological kidney damages across hypertensive, diabetic, and metabolic rat models of chronic kidney disease.
Why the study?
Chronic kidney disease impairs nitric oxide/sGC signaling through oxidative stress, and this study investigated whether the novel sGC activator runcaciguat could provide an effective treatment for CKD.
Does the sGC activator runcaciguat reduce proteinuria and kidney injury in preclinical rat models of chronic kidney disease?
Does the sGC activator runcaciguat reduce proteinuria and kidney injury in preclinical rat models of chronic kidney disease?
Answers are grounded in this paper and cite their sources.
The novel sGC activator runcaciguat provides cardio-renal protection and reduces proteinuria in hypertensive and diabetic preclinical CKD models, largely independent of blood pressure lowering.
Chronic kidney diseaQueryse (CKD) is associated with oxidative stress which can interrupt the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling and decrease cyclic guanosine monophosphate (cGMP) production. Low cGMP concentrations can cause kidney damage and progression of CKD. The novel sGC activator runcaciguat targets the oxidized and heme-free form of sGC, restoring cGMP production under oxidative stress. The purpose of this study is to investigate if runcaciguat could provide an effective treatment for CKD. Runcaciguat was used for the treatment not only in rat CKD models with different etiologies and comorbidities, namely of hypertensive rats, the renin transgenic (RenTG) rat, and angiotensin-supplemented (ANG-SD) rat, but also in rats with diabetic and metabolic CKD, the Zucker diabetic fatty (ZDF) rat. The treatment duration was 2 to 42 weeks and runcaciguat was applied orally in doses from 1 to 10 mg/kg/bid. In these different rat CKD models, runcaciguat significantly reduced proteinuria (urinary protein to creatinine ratio; uPCR). These effects were also significant at doses which did not or only moderately decrease systemic blood pressure. Moreover, runcaciguat significantly decreased kidney injury biomarkers and attenuated morphological kidney damages. In RenTG rats, runcaciguat improved survival rates and markers of heart injury. These data demonstrate that the sGC activator runcaciguat exhibits cardio-renal protection at doses which did not reduce blood pressure and was effective in hypertensive as well as diabetic and metabolic CKD models. These data, therefore, suggest that runcaciguat, with its specific mode of action, represents an efficient treatment approach for CKD and associated CV diseases.
No takes yet. Share an insight, caveat, or question.
Bénardeau et al. (2021) studied Chronic kidney disease (preclinical models) (n=178). Runcaciguat vs. Vehicle/Placebo was evaluated on Proteinuria (urinary protein to creatinine ratio; uPCR) (p=<0.05). Runcaciguat significantly reduced proteinuria, decreased kidney injury biomarkers, and attenuated morphological kidney damages across hypertensive, diabetic, and metabolic rat models of chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: